কম্বোসেফ ট্যাবলেট খাওয়ার নিয়ম কি?

Pharyngitis or tonsillitis:- (Duo LS) 100 mg 12 hourly for 5 to 10 days

Uncomplicated urinary tract infections: (Duo LS) 100 mg 12 hourly for 7 days

Complicated urinary tract infections: (Duo) 200 mg 12 hourly for7 days

Acute community acquired pneumonia: (Duo) 200 mg 12 hourly for 14 days

Acute bacterial exacerbations of chronic bronchitis: (Duo) 200 mg 12 hourly for 10 days

Uncomplicated gonorrhea and rectal gonococcal infections: (Duo) single dose

Skin and skin structure infections: (Duo) 20000 mg 12 hourly for 7 to 14 days

Acute maxillary sinusitis: (Duo) 200 mg 12 hourly for 10 days

Enteric fever: (Duo) 200 mg 12 hourly for 7 to 14 days

Patients with renal dysfunction: For patients with severe renal impairment (< 30 ml/min creatinine clearance), the dosing intervals should be increased to 24 hourly. In patients maintained on hemodialysis, the dose frequency should be 3 times/week after hemodialysis.

Patients with cirrhosis: Cefpodoxime pharmacokinetics in cirrhotic patients (with or without ascites) is similar to those in healthy subjects. Dose adjustment is not necessary in this population.

Patients with renal dysfunction: For patients with severe renal impairment (< 30 ml/min creatinine clearance), the dosing intervals should be increased to 24 hourly. In patients maintained on hemodialysis, the dose frequency should be 3 times/week after hemodialysis.

Patients with cirrhosis: Cefpodoxime pharmacokinetics in cirrhotic patients (with or without ascites) is similar to those in healthy subjects. Dose adjustment is not necessary in this population.

Probenecid: Renal excretion of Cefpodoxime proxetil was inhibited by Probenecid and resulted in an approximately 31% increase in AUC.

Nephrotoxic drugs: Close monitoring of renal function is advised when Cefpodoxime proxetil is administered concomitantly with compounds of known nephrotoxic potential.

কম্বোসেফ ট্যাবলেট সম্পর্কে বিস্তারিত জেনে নিন এই লিঙ্ক থেকে কম্বোসেফ